Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer

JAMA

Volumn 277, Issue 18, 1997, Pages 1456-1460

  Carter, H Ballentine ^a,d   Epstein, Jonathan I ^a   Chan, Daniel W ^a   Fozard, James L ^b   Pearson, Jay D ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COST CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0030948926     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.18.1456     Document Type: Article

References (20)

1. US Preventive Services Task Force. Screening for prostate cancer. In: Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996:119-134.
2. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42-46.
3. Shock NW, Greulich RC, Andres R, et al. Normal Human Aging: The Baltimore Longitudinal Study of Aging. Washington, DC: US Government Printing Office; November 1984. NIH publication 84-2450.
4. Carter HB, Pearson JD, Metter JE, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-2220.
5. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270:860-864.
6. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-374.
7. Epstein JI, Carmichael M, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term follow-up. J Urol. 1993;150:135-141.
8. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression following radical retropubic prostatectomy. Cancer. 1993;71:3582-3593.
9. Partin AW, Epstein JI, Cho KR, Gittelsohn MA, Walsh PC. Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol. 1989;141:341-345.
10. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996;20: 286-292.
11. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
12. Stone CJ, Koo CY. Additive splines in statistics. In: Proceedings of the Statistical Computing Section of the American Statistical Association. Washington, DC: 1985:45-48.
13. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273:289-294.
14. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
15. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Wittemore AS, Schmid H-P. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933-938.
16. Carter HB, Pearson JD, Waclawiw Z, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval in prostate-specific antigen velocity. Urology. 1995; 45:591-596.
17. Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/mL range in male volunteers. J Urol. 1996;155:1977-1980.
18. Smith DS, Catalona WJ, Hersehman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996;276:1309-1315.
19. Jacobsen SJ, Klee GG, Lilja H, Wright GL, Oesterling JE. Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. Urology. 1995;45:447-453.
20. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol. 1996;155:816-820.